Correlation Study Between Neoadjuvant Chemotherapy Response and Long-Term Prognosis in Breast Cancer Based on Deep Learning Models.
Source check: Source checked. Not independent scientific confirmation.
Finding: A retrospective 832-patient breast-cancer cohort used an MLP to predict five-year recurrence/metastasis after neoadjuvant chemotherapy; the model reported internal cross-validated discrimination across subtypes.
Technology: A PyTorch MLP integrated molecular subtype, grade, tumor-size reduction, nodal status, Miller–Payne grade, Ki-67 and surgery; five-fold CV and SHAP were used.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- A PyTorch MLP integrated molecular subtype, grade, tumor-size reduction, nodal status, Miller–Payne grade, Ki-67 and surgery; five-fold CV and SHAP were used.
- Test and result
- The study predicts recorded five-year recurrence/metastasis; MLP AUC 0.86 (95% CI 0.81–0.92), accuracy 0.86, F1 0.84; a retrospective result, not treatment effect.
- Limitation / still unknown
- Five-fold internal CV was reported on 832 patients from one retrospective cohort. No external or prospective validation is established; evidence supports only the source-reported prognostic result.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.mdpi.com/2075-4418/15/21/2763/xml
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.